First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial

The purpose of our study was to compare progression-free survival and quality of life (QOL) after cisplatin–gemcitabine (CG) or epirubicin–gemcitabine (EG) in chemotherapy-naive patients with unresectable non-small-cell lung cancer. Patients (n=240) were randomised to receive gemcitabine 1125 mg m(−...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wachters, F M, van Putten, J W G, Kramer, H, Erjavec, Z, Eppinga, P, Strijbos, J H, de Leede, G P J, Boezen, H M, de Vries, E G E, Groen, H J M
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2003
Matèries:
Clinical
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394313/
https://ncbi.nlm.nih.gov/pubmed/14520444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601283
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars